165 related articles for article (PubMed ID: 16540898)
21. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.
Hu C; Li H; Li J; Zhu Z; Yin S; Hao X; Yao M; Zheng S; Gu J
Carcinogenesis; 2008 Dec; 29(12):2289-97. PubMed ID: 18820285
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor biology in head and neck cancer.
Kalyankrishna S; Grandis JR
J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
[TBL] [Abstract][Full Text] [Related]
23. Baicalein decreases side population proportion via inhibition of ABCG2 in multiple myeloma cell line RPMI 8226 in vitro.
Gu YY; Liu LP; Qin J; Zhang M; Chen Y; Wang D; Li Z; Tang JZ; Mo SL
Fitoterapia; 2014 Apr; 94():21-8. PubMed ID: 24468191
[TBL] [Abstract][Full Text] [Related]
24. Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.
Tepper SR; Zuo Z; Khattri A; Heß J; Seiwert TY
Oral Oncol; 2016 May; 56():62-70. PubMed ID: 27086488
[TBL] [Abstract][Full Text] [Related]
25. Tumor associated macrophages induce epithelial to mesenchymal transition via the EGFR/ERK1/2 pathway in head and neck squamous cell carcinoma.
Gao L; Zhang W; Zhong WQ; Liu ZJ; Li HM; Yu ZL; Zhao YF
Oncol Rep; 2018 Nov; 40(5):2558-2572. PubMed ID: 30132555
[TBL] [Abstract][Full Text] [Related]
26. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a side population of astrocytoma cells in response to temozolomide.
Chua C; Zaiden N; Chong KH; See SJ; Wong MC; Ang BT; Tang C
J Neurosurg; 2008 Nov; 109(5):856-66. PubMed ID: 18976075
[TBL] [Abstract][Full Text] [Related]
28. ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer.
Xie ZY; Lv K; Xiong Y; Guo WH
Oncol Res Treat; 2014; 37(11):666-8, 670-2. PubMed ID: 25427584
[TBL] [Abstract][Full Text] [Related]
29. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.
Meissner M; Reichert TE; Kunkel M; Gooding W; Whiteside TL; Ferrone S; Seliger B
Clin Cancer Res; 2005 Apr; 11(7):2552-60. PubMed ID: 15814633
[TBL] [Abstract][Full Text] [Related]
30. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
[TBL] [Abstract][Full Text] [Related]
31. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
[TBL] [Abstract][Full Text] [Related]
33. Ocular surface epithelia contain ABCG2-dependent side population cells exhibiting features associated with stem cells.
Budak MT; Alpdogan OS; Zhou M; Lavker RM; Akinci MA; Wolosin JM
J Cell Sci; 2005 Apr; 118(Pt 8):1715-24. PubMed ID: 15811951
[TBL] [Abstract][Full Text] [Related]
34. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
35. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
Elkind NB; Szentpétery Z; Apáti A; Ozvegy-Laczka C; Várady G; Ujhelly O; Szabó K; Homolya L; Váradi A; Buday L; Kéri G; Német K; Sarkadi B
Cancer Res; 2005 Mar; 65(5):1770-7. PubMed ID: 15753373
[TBL] [Abstract][Full Text] [Related]
36. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
Krohn V; Wiegand S; Werner JA; Mandic R
Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
[TBL] [Abstract][Full Text] [Related]
37. Isolation and characterization of cancer stem-like side population cells in human oral cancer cells.
Yanamoto S; Kawasaki G; Yamada S; Yoshitomi I; Kawano T; Yonezawa H; Rokutanda S; Naruse T; Umeda M
Oral Oncol; 2011 Sep; 47(9):855-60. PubMed ID: 21757396
[TBL] [Abstract][Full Text] [Related]
38. Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells.
Kim JB; Ko E; Han W; Shin I; Park SY; Noh DY
Planta Med; 2008 Nov; 74(14):1693-700. PubMed ID: 18951337
[TBL] [Abstract][Full Text] [Related]
39. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu L
Br J Pharmacol; 2015 Aug; 172(16):4089-106. PubMed ID: 25988710
[TBL] [Abstract][Full Text] [Related]
40. Ah receptor antagonism represses head and neck tumor cell aggressive phenotype.
DiNatale BC; Smith K; John K; Krishnegowda G; Amin SG; Perdew GH
Mol Cancer Res; 2012 Oct; 10(10):1369-79. PubMed ID: 22912337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
